Brief: AC Immune To Regain Global Rights To Crenezumab And Semorinemab
22/01/2024 12:31
Jan 22 (Reuters) - AC Immune SA ACIU.O :
* AC IMMUNE TO REGAIN GLOBAL RIGHTS TO CRENEZUMAB AND
SEMORINEMAB
* AC IMMUNE SA-TO REGAIN RIGHTS TO EXISTING GMP DRUG-PRODUCT
FOR
CLINICAL TESTING AS WELL AS ASSOCIATED DATA GENERATED UNDER EACH
OF AGREEMENTS WITH GENENTECH
Source text for Eikon: ID:nGNX25nrJv
Further company coverage: ACIU.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AC Immune SA
See all newsBrief: Ac Immune To Receive Research Grant From Goradia Family For Development Of Aci-7104 In Parkinson’S Disease
AC Immune Q1 net loss narrows on lower expenses
Brief: AC Immune Announces Amendment To Morphomer ® Tau License And Collaboration Agreement With Lilly
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture